ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -29 مورد

Probenecid: Pediatric drug information

Probenecid: Pediatric drug information
2025© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Probenecid: Drug information" and "Probenecid: Patient drug information"

For abbreviations, symbols, and age group definitions show table
Therapeutic Category
  • Adjuvant Therapy, Penicillin Level Prolongation;
  • Antigout Agent;
  • Uric Acid Lowering Agent;
  • Uricosuric Agent
Dosing: Pediatric
Pharmacokinetic enhancer, penicillin antibiotics

Pharmacokinetic enhancer, penicillin antibiotics:

Children ≥2 years and Adolescents: Note: Dosing for specific indications may vary; use has also been described with some cephalosporins (Ref).

Patient weight ≤50 kg:

Weight-directed dosing:

Initial: Oral: 25 mg/kg/dose as a single dose.

Maintenance: Oral: 10 mg/kg/dose 4 times daily; maximum dose: 500 mg/dose.

BSA-directed dosing:

Initial: Oral: 700 mg/m2/dose as a single dose.

Maintenance: Oral: 300 mg/m2/dose 4 times daily; maximum dose: 500 mg/dose.

Patient weight >50 kg: Oral: 500 mg 4 times daily.

Sexually transmitted infections, as a beta-lactam pharmacokinetic enhancer

Sexually transmitted infections, as a beta-lactam pharmacokinetic enhancer (adjunctive agent):

Gonococcal infection, uncomplicated infection of cervix, urethra, or rectum: Adolescents: Oral: 1,000 mg as a single dose concomitantly with a single dose of cefoxitin (Ref).

Pelvic inflammatory disease: Children weighing ≥45 kg and Adolescents: Oral: 1,000 mg as a single dose, concomitantly with a single dose of cefoxitin (as part of an appropriate combination regimen) (Ref).

Neurosyphilis (alternative regimen): Note: IV therapy is preferred. Use only in patients in whom compliance can be ensured (Ref).

Adolescents: Oral: 500 mg 4 times daily with procaine penicillin for 10 to 14 days (Ref).

Cidofovir nephrotoxicity, prevention

Cidofovir nephrotoxicity, prevention: Limited data available; various regimens have been reported:

Infants, Children, and Adolescents: Note: The manufacturer's labeling considers use in patients <2 years of age to be contraindicated; however, clinical studies have included younger ages (including infants) for this indication. Use in combination with IV fluid hydration.

Weight-directed dosing: Oral: 25 to 40 mg/kg/dose (maximum dose: 2,000 mg/dose) administered 3 hours before cidofovir infusion and 10 to 20 mg/kg/dose (maximum dose: 1,000 mg/dose) at 2 to 3 hours and 8 to 9 hours after cidofovir infusion (Ref).

BSA-directed dosing: Oral: 1,000 or 1,250 mg/m2/dose (maximum dose: 2,000 mg/dose) administered 3 hours prior to cidofovir, followed by 500 to 1,250 mg/m2/dose (maximum dose: 1,000 mg/dose) 1 to 3 hours and 8 hours after completion (Ref).

Dosing: Kidney Impairment: Pediatric

Children ≥2 years and Adolescents: CrCl <30 mL/minute: Avoid use (reduced efficacy with renal impairment).

Dosing: Liver Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Adult

(For additional information see "Probenecid: Drug information")

Cidofovir nephrotoxicity, prevention

Cidofovir nephrotoxicity, prevention (off-label use): Oral: 2 g as a single dose administered 3 hours before cidofovir infusion, followed by 1 g at 2 hours and 8 hours after cidofovir infusion (Ref).

Hyperuricemia, gout prevention

Hyperuricemia, gout prevention (alternative agent): Oral: 250 mg twice daily for 1 week, followed by 500 mg twice daily; may increase dose by 500 mg every 4 weeks as tolerated if symptoms are not controlled; usual maintenance dose: ≤2 g/day in divided doses.

Sexually transmitted infections, as a beta-lactam pharmacokinetic enhancer

Sexually transmitted infections, as a beta-lactam pharmacokinetic enhancer (adjunctive agent):

Gonococcal infection, uncomplicated: Oral: 1 g as a single dose in combination with single-dose IM cefoxitin (Ref).

Neurosyphilis, including ocular and otosyphilis:

Note: Reserve for patients unable to receive IV therapy (Ref).

Oral: 500 mg 4 times daily in combination with IM procaine penicillin for 10 to 14 days (Ref).

Pelvic inflammatory disease, mild to moderate: Oral: 1 g as a single dose in combination with IM cefoxitin as a single dose plus doxycycline and metronidazole (Ref).

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Altered kidney function

eGFR ≥60 mL/minute/1.73 m2: No dosage adjustment necessary (Ref).

eGFR <60 mL/minute/1.73 m2:

Cidofovir nephrotoxicity, prevention (off-label use):

Oral: No dosage adjustment of probenecid likely necessary (Ref). Note: The use and dose of cidofovir in patients with kidney dysfunction should be evaluated separately.

Hyperuricemia, gout prevention: Oral:

eGFR ≥30 to <60 mL/minute/1.73 m2: The use of alternative agents is recommended due to reduced efficacy of probenecid in patients with eGFR <60 mL/minute/1.73 m2 (Ref). If use of probenecid is deemed appropriate, no dosage adjustment likely necessary; however, use with caution and frequent monitoring for safety and efficacy. Limited data demonstrate urate-lowering capability of probenecid in patients with eGFR 30 to 60 mL/minute/1.73 m2 without increased risk of toxicity; however, robust evidence is lacking, and better alternatives are often available (Ref).

eGFR <30 mL/minute/1.73 m2: Use not recommended (Ref).

Sexually transmitted infections, as a pharmacokinetic enhancer to prolong beta-lactam serum levels: Oral:

Note: No dosage adjustment is necessary for single dose probenecid regimens (ie, used in combination with cefoxitin for gonococcal infection or pelvic inflammatory disease) (Ref).

eGFR <60 mL/minute/1.73 m2: Since probenecid may have limited efficacy in reducing the renal clearance of beta-lactam concentrations (ie, procaine penicillin) in patients with kidney impairment, the use of probenecid in combination with procaine penicillin for the treatment of neurosyphilis should be avoided (Ref).

Hemodialysis, intermittent (thrice weekly): Oral: Avoid use (Ref).

Peritoneal dialysis: Oral: Avoid use (Ref).

CRRT: Oral: Avoid use (Ref).

PIRRT (eg, sustained, low-efficiency diafiltration): Oral: Avoid use (Ref).

Dosing: Liver Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Adverse Reactions

The following adverse drug reactions are derived from product labeling unless otherwise specified.

Frequency not defined:

Cardiovascular: Flushing

Dermatologic: Alopecia, dermatitis, pruritus, urticaria

Gastrointestinal: Anorexia, gingival pain, nausea, vomiting

Genitourinary: Urinary frequency

Hematologic & oncologic: Anemia, aplastic anemia, hemolytic anemia, leukopenia

Hepatic: Hepatic necrosis

Nervous system: Dizziness, headache, pain (costovertebral)

Renal: Nephrolithiasis, nephrotic syndrome, renal colic

Miscellaneous: Fever

Postmarketing: Hypersensitivity: Anaphylaxis, severe hypersensitivity reaction

Contraindications

Hypersensitivity to probenecid or any component of the formulation; blood dyscrasias; uric acid kidney stones; children <2 years of age; initiation during an acute gout attack.

Warnings/Precautions

Concerns related to adverse effects:

• Hypersensitivity reaction: Has been associated with rare, severe hypersensitivity reactions, including anaphylaxis. Discontinue therapy if reaction occurs.

• Gout: May cause exacerbation of acute gouty attack.

Disease-related concerns:

• G6PD deficiency: Use caution in patients with G6PD deficiency; may increase risk for hemolytic anemia.

• Peptic ulcer disease: Use with caution in patients with peptic ulcer disease.

• Kidney impairment: May not be effective in patients with kidney impairment; use with caution (ACR [FitzGerald 2020]; manufacturer’s labeling).

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Generic: 500 mg

Generic Equivalent Available: US

Yes

Pricing: US

Tablets (Probenecid Oral)

500 mg (per each): $0.98 - $3.73

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Administration: Pediatric

Oral: Administer with food to minimize GI effects (Ref).

Administration: Adult

Oral: Administer with food to minimize GI effects. Maintain adequate fluid intake.

Storage/Stability

Store at 20°C to 25°C (68°F to 77°F). Protect from light.

Use

Adjuvant to therapy with penicillins to elevate and prolong serum concentrations (FDA approved in ages ≥2 years and adults); treatment of hyperuricemia associated with gout and gouty arthritis (FDA approved in adults); has also been used with cephalosporin therapy to prolong serum concentrations and to prevent nephrotoxicity associated with cidofovir therapy.

Medication Safety Issues
Sound-alike/look-alike issues:

Probenecid may be confused with Procanbid

Metabolism/Transport Effects

Inhibits MRP2, OAT1/3, UGT1A4, UGT1A6;

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program

Acetaminophen: Probenecid may increase serum concentration of Acetaminophen. Probenecid may also limit the formation of at least one major non-toxic metabolite, possibly increasing the potential for formation of the toxic NAPQI metabolite. Management: Consider limiting acetaminophen use in combination with probenecid. Probenecid may reduce clearance of acetaminophen to one of its non-toxic metabolities, increasing the risk for acetaminophen toxicity, even a lower doses. Risk D: Consider Therapy Modification

Anagliptin: Probenecid may increase serum concentration of Anagliptin. Risk C: Monitor

Avibactam: Probenecid may increase serum concentration of Avibactam. Risk X: Avoid

Baricitinib: Probenecid may increase serum concentration of Baricitinib. Management: When baricitinib is combined with probenecid, reduce baricitinib 4 mg daily to 2 mg daily or reduce baricitinib 2 mg daily to 1 mg daily. Don't use probenecid if recommended baricitinib dose is only 1 mg daily. Risk D: Consider Therapy Modification

Betalactamase Inhibitors: Probenecid may increase serum concentration of Betalactamase Inhibitors. Management: Coadministration of probenecid with amoxicillin/clavulanate is not recommended per official package labeling. Risk D: Consider Therapy Modification

Cabozantinib: MRP2 Inhibitors may increase serum concentration of Cabozantinib. Risk C: Monitor

Cefotaxime: Probenecid may increase serum concentration of Cefotaxime. Management: Avoid cefotaxime doses greater than 6 grams per day with concurrent probenecid. Any patients receiving this combination should be monitored for evidence of cefotaxime toxicity. Risk D: Consider Therapy Modification

Cephalosporins: Probenecid may increase serum concentration of Cephalosporins. Risk C: Monitor

Certoparin: Probenecid may increase anticoagulant effects of Certoparin. Risk C: Monitor

Clofarabine: OAT1/3 Inhibitors may increase serum concentration of Clofarabine. Risk C: Monitor

Deferiprone: UGT1A6 Inhibitors may increase serum concentration of Deferiprone. Risk X: Avoid

Dexketoprofen: Probenecid may increase serum concentration of Dexketoprofen. Risk C: Monitor

Dichlorphenamide: OAT1/3 Inhibitors may increase serum concentration of Dichlorphenamide. Risk C: Monitor

Doripenem: Probenecid may increase serum concentration of Doripenem. Risk X: Avoid

Dyphylline: Probenecid may increase serum concentration of Dyphylline. Risk C: Monitor

Ertapenem: Probenecid may increase serum concentration of Ertapenem. Risk X: Avoid

Ganciclovir-Valganciclovir: Probenecid may increase serum concentration of Ganciclovir-Valganciclovir. Risk C: Monitor

Gemifloxacin: Probenecid may increase serum concentration of Gemifloxacin. Risk C: Monitor

Imipenem: Probenecid may increase serum concentration of Imipenem. Risk C: Monitor

Ketoprofen: Probenecid may increase serum concentration of Ketoprofen. Risk X: Avoid

Ketorolac (Nasal): Probenecid may increase serum concentration of Ketorolac (Nasal). Risk X: Avoid

Ketorolac (Systemic): Probenecid may increase serum concentration of Ketorolac (Systemic). Risk X: Avoid

Loop Diuretics: Probenecid may decrease diuretic effects of Loop Diuretics. Probenecid may increase serum concentration of Loop Diuretics. Risk C: Monitor

LORazepam: Probenecid may increase serum concentration of LORazepam. Management: Reduce lorazepam dose 50% during coadministration with probenecid. Monitor for increased and prolonged lorazepam effects, particularly CNS depressant effects. Patients using lorazepam ER capsules should be switched to lorazepam tablets. Risk D: Consider Therapy Modification

Meropenem: Probenecid may increase serum concentration of Meropenem. Risk X: Avoid

Methotrexate: Probenecid may increase serum concentration of Methotrexate. Management: If possible, the concomitant use of methotrexate and probenecid should be avoided. If used concomitantly, monitor closely for increased methotrexate serum concentrations and toxicities. Methotrexate dose reductions may be needed. Risk D: Consider Therapy Modification

Mycophenolate: Probenecid may increase serum concentration of Mycophenolate. Risk C: Monitor

Nitrofurantoin: Probenecid may decrease therapeutic effects of Nitrofurantoin. Probenecid may increase serum concentration of Nitrofurantoin. Risk C: Monitor

Nonsteroidal Anti-Inflammatory Agents: Probenecid may increase serum concentration of Nonsteroidal Anti-Inflammatory Agents. Risk C: Monitor

Oseltamivir: Probenecid may increase active metabolite exposure of Oseltamivir. Risk C: Monitor

Pegloticase: Probenecid may increase adverse/toxic effects of Pegloticase. Specifically, Probenecid may blunt increases in serum urate that would signal an elevated risk of anaphylaxis and infusion reactions. Risk X: Avoid

Penicillins: Probenecid may increase serum concentration of Penicillins. Risk C: Monitor

Pexidartinib: UGT1A4 Inhibitors may increase serum concentration of Pexidartinib. Management: If combined use cannot be avoided, pexidartinib dose should be reduced as follows: reduce pexidartinib doses of 500 mg or 375 mg daily to 125 mg twice daily; reduce pexidartinib 250 mg daily to 125 mg once daily. Risk D: Consider Therapy Modification

Phenprocoumon: Probenecid may decrease serum concentration of Phenprocoumon. Risk C: Monitor

PRALAtrexate: Probenecid may increase serum concentration of PRALAtrexate. Management: Avoid coadministration of pralatrexate with probenecid. If coadministration cannot be avoided, closely monitor for increased pralatrexate serum concentrations or possible toxicity with concomitant use of probenecid. Risk D: Consider Therapy Modification

Propacetamol: Probenecid may increase active metabolite exposure of Propacetamol. Specifically, accetaminophen exposure may be increased. Probenecid may also limit the formation of at least one major non-toxic acetaminophen metabolite, possibly increasing the formation of the toxic NAPQI metabolite. Management: Consider limiting the use of propacetamide in patients who are also taking probenecid. Patients may be at an increased risk for toxicity, even if reduced propacetamide doses are used. Risk D: Consider Therapy Modification

Quinolones: Probenecid may increase serum concentration of Quinolones. Probenecid may decrease excretion of Quinolones. Specifically, probenecid may decreased the renal excretion of quinolone antibiotics. Risk C: Monitor

RifAMPin: Probenecid may increase serum concentration of RifAMPin. Risk C: Monitor

Roxadustat: Probenecid may increase serum concentration of Roxadustat. Risk C: Monitor

Salicylates: May decrease therapeutic effects of Probenecid. Salicylates may increase serum concentration of Probenecid. Probenecid may increase serum concentration of Salicylates. Risk X: Avoid

Seladelpar: OAT1/3 Inhibitors may increase serum concentration of Seladelpar. Risk X: Avoid

Sodium Benzoate: Probenecid may decrease therapeutic effects of Sodium Benzoate. Risk C: Monitor

Sulbactam: Probenecid may increase serum concentration of Sulbactam. Management: Recommendations for management of this interaction vary by specific sulbactam-containing product. Coadministration of probenecid with sulbactam/durlobactam is not recommended, but no specific actions are recommended for ampicillin/sulbactam. Risk D: Consider Therapy Modification

Sulfonylureas: Probenecid may increase serum concentration of Sulfonylureas. Risk C: Monitor

Thiopental: Probenecid may increase adverse/toxic effects of Thiopental. Specifically, anesthetic potency and duration may be enhanced. Risk C: Monitor

Urea Cycle Disorder Agents: Probenecid may increase active metabolite exposure of Urea Cycle Disorder Agents. Specifically, concentrations of phenylacetate and phenylacetylglutamine may be increased. Risk C: Monitor

Vadadustat: OAT1/3 Inhibitors may increase serum concentration of Vadadustat. Risk C: Monitor

Zidovudine: Probenecid may increase serum concentration of Zidovudine. Risk C: Monitor

Dietary Considerations

Drug may cause GI upset; take with food if GI upset. Drink plenty of fluids.

Pregnancy Considerations

Probenecid crosses the placenta.

Outcome data following maternal use of probenecid during pregnancy are limited (Gutman 2012).

Monitoring Parameters

Kidney function, CBC; monitor for GI upset.

Mechanism of Action

Competitively inhibits the reabsorption of uric acid at the proximal convoluted tubule, thereby promoting its excretion and reducing serum uric acid levels; increases plasma levels of weak organic acids (penicillins, cephalosporins, or other beta-lactam antibiotics) by competitively inhibiting their renal tubular secretion

Pharmacokinetics (Adult Data Unless Noted)

Onset of action: Effect on penicillin levels: 2 hours; Uric acid renal clearance: 30 minutes

Absorption: Rapid and complete

Protein binding: 85% to 95%

Metabolism: Hepatic

Half-life elimination (dose dependent): Normal renal function: 6 to 12 hours

Time to peak, serum: 2 to 4 hours

Excretion: Urine

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Benemid;
  • (AU) Australia: Benemid | Pro cid;
  • (CH) Switzerland: Santuril;
  • (CZ) Czech Republic: Benemid;
  • (EE) Estonia: Benemid | Probenecid biokanol;
  • (FI) Finland: Probecid;
  • (FR) France: Benemide | Probenecid biokanol | Santuril;
  • (GB) United Kingdom: Benemid;
  • (GR) Greece: Benemid;
  • (HU) Hungary: Benemid;
  • (ID) Indonesia: Probenid;
  • (IE) Ireland: Benemid;
  • (IN) India: Bencid;
  • (IT) Italy: Probenec;
  • (JP) Japan: Benecid | Probenemid;
  • (LT) Lithuania: Benemid;
  • (LV) Latvia: Benemid | Probenecid Weimer;
  • (MX) Mexico: Benecid;
  • (NL) Netherlands: Benemid;
  • (NO) Norway: Probecid;
  • (PH) Philippines: Benemid;
  • (PL) Poland: Benemid | Benemide | Probenecid Weimer;
  • (PR) Puerto Rico: Benemid;
  • (PT) Portugal: Benemid;
  • (RU) Russian Federation: Probenecid biokanol;
  • (SE) Sweden: Probecid;
  • (TH) Thailand: Bencid | Benecid | Benemid | Proben;
  • (TN) Tunisia: Benemide;
  • (TW) Taiwan: Benemid | Brucid | Procid | Pronid;
  • (UA) Ukraine: Santuril;
  • (ZA) South Africa: Proben
  1. 2019 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019;67(4):674-694. doi:10.1111/jgs.15767 [PubMed 30693946]
  2. American Academy of Pediatrics (AAP). In: Kimberlin DW, Banerjee R, Barnett ED, Lynfield R, Sawyer MH, eds. Red Book: 2024-2027 Report of the Committee on Infectious Diseases. 33rd ed. American Academy of Pediatrics; 2024.
  3. Anderson EJ, Guzman-Cottrill JA, Kletzel M, et al. High-risk adenovirus-infected pediatric allogeneic hematopoietic progenitor cell transplant recipients and preemptive cidofovir therapy. Pediatr Transplant. 2008;12(2):219-227. doi:10.1111/j.1399-3046.2007.00851.x [PubMed 18307672]
  4. Anderson PO, Sauberan JB. Modeling drug passage into human milk. Clin Pharmacol Ther. 2016;100(1):42-52. doi:10.1002/cpt.377 [PubMed 27060684]
  5. Bhadri VA, Lee-Horn L, Shaw PJ. Safety and Tolerability of Cidofovir in High-Risk Pediatric Patients. Transpl Infect Dis. 2009;11(4):373-379. [PubMed 19392729]
  6. Brody SR, Humphreys MH, Gambertoglio JG, Schoenfeld P, Cundy KC, Aweeka FT. Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis. Clin Pharmacol Ther. 1999;65(1):21-28. doi:10.1016/S0009-9236(99)70118-9 [PubMed 9951427]
  7. Caruso Brown AE, Cohen MN, Tong S, et al. Pharmacokinetics and safety of intravenous cidofovir for life-threatening viral infections in pediatric hematopoietic stem cell transplant recipients. Antimicrob Agents Chemother. 2015;59(7):3718-3725. doi:10.1128/AAC.04348-14 [PubMed 25733509]
  8. Case R, Wentworth B, Jester G. Effective uric acid reduction with probenecid and febuxostat in a patient with chronic kidney disease. BMJ Case Rep. 2018;2018:bcr2017222845. doi:10.1136/bcr-2017-222845 [PubMed 29386212]
  9. Cesaro S, Zhou X, Manzardo C, et al. Cidofovir for Cytomegalovirus Reactivation in Pediatric Patients After Hematopoietic Stem Cell Transplantation. J Clin Virol. 2005;34(2):129-132. [PubMed 16157264]
  10. Doan ML, Mallory GB, Kaplan SL, et al. Treatment of Adenovirus Pneumonia With Cidofovir in Pediatric Lung Transplant Recipients. J Heart Lung Transplant. 2007;26(9):883-889. [PubMed 17845926]
  11. Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
  12. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020;72(6):744-760. doi:10.1002/acr.24180 [PubMed 32391934]
  13. Florescu DF, Chambers HE, Qiu F, et al. Cidofovir in pediatric solid organ transplant recipients: University of Nebraska experience. Pediatr Infect Dis J. 2015;34(1):47-51. doi:10.1097/INF.0000000000000487 [PubMed 25010830]
  14. Florescu DF, Schaenman JM; AST Infectious Diseases Community of Practice. Adenovirus in solid organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13527. doi:10.1111/ctr.13527 [PubMed 30859626]
  15. Gutman J, Kachur SP, Slutsker L, et al. Combination of Probenecid-Sulphadoxine-Pyrimethamine for intermittent Preventive Treatment in Pregnancy. Malar J. 2012;11:39. [PubMed 22321288]
  16. Ilett KF, Hackett LP, Ingle B, et al, “Transfer of Probenecid and Cephalexin into Breast Milk,” Ann Pharmacother, 2006, 40(5):986-9. [PubMed 16551765]
  17. Ito S. Drug therapy for breast-feeding women. N Engl J Med. 2000;343(2):118-126. doi:10.1056/NEJM200007133430208 [PubMed 10891521]
  18. Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Gout. Rheumatology (Oxford). 2007;46(8):1372-4. Available at http://rheumatology.oxfordjournals.org/content/suppl/2008/02/21/kem056a.DC1/kem056b.pdf [PubMed 17522099]
  19. Khangura S, Wallace J, Kissoon N, Kodeeswaran T. Management of cellulitis in a pediatric emergency department. Pediatr Emerg Care. 2007;23(11):805-811. doi:10.1097/PEC.0b013e31815a032f [PubMed 18007211]
  20. LoPresti AE, Levine JF, Munk GB, Tai CY, Mendel DB. Successful treatment of an acyclovir- and foscarnet-resistant herpes simplex virus type 1 lesion with intravenous cidofovir. Clin Infect Dis. 1998;26(2):512-513. doi:10.1086/517101 [PubMed 9502489]
  21. Montgomery M. Gout: Tips on diagnosis, treatment, and patient education. Nurse Pract. 2008;33(12):28-32. doi:10.1097/01.NPR.0000342180.40414.be [PubMed 19057345]
  22. Permpalung N, Mahoney MV, Alonso CD. Adjunctive use of cidofovir and intravenous immunoglobulin to treat invasive adenoviral disease in solid organ transplant recipients. Pharmacotherapy. 2018;38(12):1260-1266. doi:10.1002/phar.2194 [PubMed 30403300]
  23. Probenecid tablet [prescribing information]. Philadelphia, PA: Lannett Company Inc; November 2022.
  24. Probenecid tablet [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals; April 2024.
  25. Pui K, Gow PJ, Dalbeth N. Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population. J Rheumatol. 2013;40(6):872-876. doi:10.3899/jrheum.121301 [PubMed 23457380]
  26. Refer to manufacturer's labeling.
  27. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29-42. doi: 10.1136/annrheumdis-2016-209707. [PubMed 27457514]
  28. Riggsbee DL, Alali M, Kussin ML. Cidofovir for viral infections in immunocompromised children: guidance on dosing, safety, efficacy, and a review of the literature. Ann Pharmacother. 2024;58(3):286-304. doi:10.1177/10600280231176135 [PubMed 37272472]
  29. Siew JX, Seah XFV, Chew YR, et al. Epidemiology of adenovirus infections and outcomes of cidofovir treatment in severely ill children. Pediatr Infect Dis J. 2020;39(10):907-913. doi:10.1097/INF.0000000000002726 [PubMed 32404785]
  30. Stocker SL, Graham GG, McLachlan AJ, Williams KM, Day RO. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. J Rheumatol. 2011;38(5):904-910. doi:10.3899/jrheum.101160 [PubMed 21285173]
  31. US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Updated May 26, 2020. Accessed January 21, 2021.
  32. Vistide (cidofovir) [prescribing information]. Foster City, CA: Gilead; September 2010.
  33. Williams KM, Agwu AL, Dabb AA, et al, "A Clinical Algorithm Identifies High Risk Pediatric Oncology and Bone Marrow Transplant Patients Likely to Benefit From Treatment of Adenoviral infection," J Pediatr Hematol Oncol, 2009, 31(11):825-31. [PubMed 19801951]
  34. Wilson RC, Arkell P, Riezk A, et al. Addition of probenecid to oral β-lactam antibiotics: a systematic review and meta-analysis. J Antimicrob Chemother. 2022;77(9):2364-2372. doi:10.1093/jac/dkac200 [PubMed 35726853]
  35. Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1 [PubMed 34292926]
  36. Yusuf U, Hale GA, Carr J, et al. Cidofovir for the treatment of adenoviral infection in pediatric hematopoietic stem cell transplant patients. Transplantation. 2006;81(10):1398-1404. [PubMed 16732176]
  37. Zalcman J, Pasternak Y, Kenan D, et al. Safety of cidofovir treatment for suspected or confirmed adenovirus infection in immunocompetent pediatric population. Pediatr Infect Dis J. 2024;43(3):198-202. doi:10.1097/INF.0000000000004186 [PubMed 38011019]
  38. Zhang W, Doherty M, Bardin T, et al; EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312-1324. [PubMed 16707532]
Topic 12730 Version 212.0